(Circulation. 1995;91:566-579.)
© 1995 American Heart Association, Inc.
Articles |
| Abstract |
|---|
|
|
|---|
Methods A conference was held July 16-18, 1993, in Park City, Utah, that included recognized experts in neurology, neurosurgery, vascular surgery, and healthcare planning. A program of critical topics was developed, and each expert presented a talk and provided the chairman with a summary statement. From these summary statements a document was developed and edited onsite to achieve consensus before final revision.
Results The first section of this document reviews the natural history, methods of patient evaluation, options for medical management, results of surgical management, data from position statements, and results to date of prospective randomized trials for symptomatic and asymptomatic patients with carotid artery disease. The second section divides 96 potential indications for carotid endarterectomy, based on surgical risk, into four categories: (1) Proven: This is the strongest indication for carotid endarterectomy; data are supported by results of prospective contemporary randomized trials. (2) Acceptable but not proven: a good indication for operation; supported by promising but not scientifically certain data. (3) Uncertain: Data are insufficient to define the risk/benefit ratio. (4) Proven inappropriate: Current data are adequate to show that the risk of surgery outweighs any benefit.
Conclusions Indications for carotid endarterectomy in symptomatic
good-risk patients with a surgeon whose surgical morbidity and
mortality rate is less than 6% are as follows. (1) Proven:
one or more TIAs in the past 6 months and carotid stenosis
70% or mild stroke within 6 months and a carotid stenosis
70%; (2) acceptable but not proven: TIAs
within the past 6 months and a stenosis 50% to 69%, progressive
stroke and a stenosis
70%, mild or moderate stroke in the
past 6 months and a stenosis 50% to 69%, or carotid endarterectomy
ipsilateral to TIAs and a stenosis
70% combined with
required coronary artery bypass grafting; (3) uncertain:
TIAs with a stenosis <50%, mild stroke and stenosis <50%, TIAs with
a stenosis <70% combined with coronary artery bypass grafting, or
symptomatic, acute carotid thrombosis; (4) proven
inappropriate: moderate stroke with stenosis <50%, not on
aspirin; single TIA, <50% stenosis, not on aspirin; high-risk patient
with multiple TIAs, not on aspirin, stenosis <50%; high-risk patient,
mild or moderate stroke, stenosis <50%, not on aspirin; global
ischemic symptoms with stenosis <50%; acute dissection, asymptomatic
on heparin. Indications for carotid endarterectomy in asymptomatic
good-risk patients performed by a surgeon whose surgical morbidity and
mortality rate is less than 3% are as follows. (1) Proven:
none. As this statement went to press, the National Institute of
Neurological Disorders and Stroke issued a clinical advisory stating
that the Institute has halted the Asymptomatic Carotid Atherosclerosis
Study (ACAS) because of a clear benefit in favor of surgery for
patients with carotid stenosis
60% as measured by diameter
reduction. When the ACAS report is published, this indication will
be recategorized as proven. (2) acceptable but not
proven: stenosis >75% by linear diameter; (3)
uncertain: stenosis >75% in a high-risk patient/surgeon
(surgical morbidity and mortality rate >3%), combined
carotid/coronary operations, or ulcerative lesions without
hemodynamically significant stenosis; (4) proven
inappropriate: operations with a combined stroke morbidity and
mortality >5%.
Key Words: carotid endarterectomy stroke clinical trials consensus statement surgery
| Introduction |
|---|
|
|
|---|
The American Heart Association assembled a group of experts in the field of cerebrovascular disease at a multidisciplinary conference to determine indications for carotid endarterectomy about which there is agreement, to highlight areas that remain controversial, and to recommend further studies or clinical trials.
The conference, held July 16 to 18, 1993, in Park City, Utah, included a review of the available data and preparation of this consensus statement.
| Consensus Process |
|---|
|
|
|---|
After the formal presentations, a list of 96 potential indications for carotid endarterectomy was circulated to the participants. The indications were based on symptom status, percent stenosis, plaque characteristics, status of opposite carotid artery, and various levels of surgical risk. Each participant was asked to rate the indication for operation with one of four options: proven; acceptable but not proven; uncertain; and proven inappropriate.
When the individual indications for carotid endarterectomy were tabulated, the first draft of the position statement was read to the entire group of participants for discussion and comment. After discussion by the consensus panel, the draft was rewritten to reflect the comments. The following day the second draft was read to the entire group for final comment, after which the manuscript was revised to this final form.
| Symptomatic Patients |
|---|
|
|
|---|
Patients with TIAs related to severe carotid stenotic lesions are at risk of stroke at the rate of 12% to 13% within the first year after onset of symptoms, with a cumulative stroke risk of approximately 30% to 35% at the end of 5 years. Those patients with hemispheric TIAs, recent TIA, increasing frequency of TIA, or high-grade stenosis have stroke rates that are probably higher than those with a remote or single event or lesser stenosis.1 2 Similar findings have been noted by D.O. Wiebers, MD, and H.J.M. Barnett, MD (unpublished data from the Rochester Epidemiological Project and NASCET).
Patients who have had a stroke continue to be at risk for subsequent strokes at the rate of 5% to 9% per year, with approximately 25% to 45% of patients having another stroke within 5 years of the original event.3 4 5
Plaque characteristics may significantly affect subsequent ischemic events. Echolucent and heterogeneous plaques have a high content of lipid or intraplaque hemorrhage that may produce plaque ulceration, leading to a greater embolic potential.6 7 8 In a study of asymptomatic patients with carotid artery disease (CAD) only 20% to 30% of these patients had echolucent plaques, in contrast to symptomatic patients, in whom echolucent plaques were present in 70% of the cohort.9 10 11 12 Cranial computed tomography of patients with carotid artery plaques demonstrates a 36% frequency of cerebral infarction in patients with echolucent plaques but only a 6% frequency in patients with echogenic plaques, suggesting that patients with echolucent or heterogeneous plaques have a neurological event rate two through four times greater than those with echogenic plaques.9 10 11 12 13
An examination of the control group of the North American Symptomatic Carotid Endarterectomy Trial (NASCET) study demonstrated that patients with high-grade carotid stenosis in the absence of angiographic evidence of ulceration had a 2-year stroke rate of 17% in contrast to a 2-year stroke rate of 30% when ulceration was present with similar degrees of stenosis.14 Finally, the percent stenosis present in the proximal internal carotid artery is the most important plaque characteristic for subsequent neurological events, including stroke. This is true in both asymptomatic and symptomatic patients. The NASCET study control group demonstrated that for every 10% increase in stenosis beyond 70%, there was an increased rate of subsequent stroke risk.14
Patient Evaluation
Atherosclerotic carotid artery occlusive
disease is part of a
systemic disease. Evaluation of patients with ischemic strokes, TIAs,
and suspected CAD should include a thorough history for the presence of
coronary and peripheral vascular occlusive disease and stroke risk
factors such as hypertension, tobacco and other substance abuse, use of
oral contraceptives, hyperlipidemia, and diabetes mellitus.
Neurological examination, blood pressure measurement in both arms and,
when appropriate, a test for postural hypotension, measurement of pulse
rate and rhythm, cardiac auscultation, and peripheral vascular
examination are essential. Arterial pulses and bruits should be
described.
Laboratory evaluation must include tests that define the presence, location, and severity of CAD. Ultrasound using pulsed Doppler has been accepted by some investigators in qualified laboratories as a satisfactory means of determining the severity of carotid artery stenosis. Duplex examinations (combined B-mode ultrasound and pulsed Doppler), when performed in settings in which the results have been consistently well validated by comparison with standard angiography, is an accepted and accurate technique for determining the severity of carotid artery stenosis. However, there is a risk of calling a high-grade stenosis total occlusion. This risk has been reported to be as high as 14% (false-positive rate)15 or as low as 1%,16 with a spectrum in between.17 18 19 Therefore, it is premature to make a definitive statement, since these techniques are still in evolution. Magnetic resonance angiography can also be helpful in providing images of the carotid artery, but at the present level of development it can overestimate or underestimate the severity of stenosis. Standard contrast angiography remains the gold standard for providing accurate images of the carotid arteries, the proximal vessels, and the intracranial circulation. In some patients being considered for carotid endarterectomy, duplex examination (in a laboratory whose accuracy has been validated) or duplex examination combined with magnetic resonance angiography may suffice for determining the severity of the extracranial portion of CAD, although arteriography remains the most reliable method of assessing the precise degree of carotid artery stenosis.
It is important to define how the degree of stenosis is measured. For instance, a 75% diameter stenosis will result in a cross-sectional area stenosis of around 90%. Similarly, if percent stenosis is based on diameter, and if the denominator is an estimated carotid bulb diameter, the percent stenosis will be greater than if the diameter of the internal carotid artery above the stenosis is used as the denominator. The carotid bulb is defined as the dilated (bulbous) first portion of the internal carotid artery just as it leaves the bifurcation. This is to be distinguished from the carotid sinus, ie, the terminal enlarged portion of the common carotid artery, which gives rise to the bifurcation of the internal and external carotid arteries. For consistency we believe that diameter stenosis, using the diameter of the internal carotid artery above the stenosis as the denominator, should be used. This is the measurement used in NASCET and the Asymptomatic Carotid Atherosclerosis Study (ACAS).
Studies that provide information about flow and/or pressure in the ophthalmic and intracranial carotid artery branches, such as transcranial Doppler, oculoplethysmography, and single-photon emission-computed tomography are also helpful for evaluating the severity and significance of CAD. Blood tests including hematocrit and platelet count are essential; prothrombin time and activated partial thromboplastin time are desirable. Brain imaging with computed tomography or magnetic resonance imaging is essential for patients with strokes and may be useful in patients with TIAs or asymptomatic patients who are considered for surgery.
An electrocardiogram is mandatory. Additional cardiac evaluation and consultation should be considered to seek potential cardiac sources of embolism that might have caused the brain ischemia and to assess the presence and severity of coexistent coronary artery disease. Neurological consultation is important for patients with neurological symptoms or signs. Some patients with concurrent medical illnesses (eg, pulmonary, renal, hematologic, hepatic, and other diseases) will require an evaluation to assess surgical risk.
Medical Management of Symptomatic Patients With Carotid Bifurcation
Disease
This topic is covered only briefly here because the main
purpose
of the conference was to discuss indications for carotid surgery.
Factors associated with increased risk of stroke related to CAD include
age, hypertension, ischemic heart disease, diabetes, hyperlipidemia,
diabetes, cigarette smoking, and high hematocrit. While it may appear
axiomatic that elimination or reduction of these risk factors would be
helpful for reducing stroke risk, there is very little evidence to
support this hypothesis, with the exception of treating hypertension
and stopping smoking.20
One of the most important approaches to the medical management of patients with CAD with respect to stroke risk reduction has been the use of antiplatelet drugs, principally aspirin. Newer drugs, such as ticlopidine, have shown some improvement over the effect of aspirin.21 22 Combination therapies such as aspirin plus dipyridamole are no better than aspirin alone. Recent aspirin trials and meta-analyses further clarify the effect of aspirin and its effect on stroke risk reduction.23 24 25 26 In the most recent meta-analysis,27 data from 18 prospective randomized trials of patients with a history of prior stroke or TIA were analyzed. In the antiplatelet drug treatment group, there were 479/5837 (8.2%) new nonfatal strokes; in the control group, there were 600/5870 (10.2%) new nonfatal strokes. Thus, antiplatelet drugs gave a 2% absolute risk reduction, or a 23% odds reduction, with respect to the end point of nonfatal stroke.
| Results of Endarterectomy for Symptomatic CAD |
|---|
|
|
|---|
Late Stroke Risk After Carotid Endarterectomy in Symptomatic
Patients
Patients who have undergone successful carotid endarterectomy
for
the indication of TIA (without perioperative stroke) continue to be at
risk for subsequent ipsilateral hemispheric stroke at the rate of 1%
to 2% per
year.33 34 35 36 37 38 39
Patients who have had successful carotid endarterectomy for the indication of prior stroke, without neurological complication, are at risk for subsequent ipsilateral stroke at the rate of 2% to 3% per year.28 40 41 42 43 44 45
Position Statements
A number of
organizations46 47 48 49 50 51
have issued
position statements on indications for carotid endarterectomy; for the
purposes of this document, statements by the following three
organizations were reviewed: the Society for Vascular
Surgery/International Society for Cardiovascular Surgery
(SVS/ISCVS),49 the Rand Corporation,50 and an
ad hoc committee of the American Medical Association (AMA) (D.B.
Matchar, MD, C.T. Huesgen, MD, W.S. Moore, MD, unpublished data). The
AMA subcommittee that reviewed the SVS/ISCVS recommendations and
compared them with the Rand panel found that the two statements were in
substantial agreement.
Indications for Carotid Endarterectomy Based on Prospective
Randomized Trials
To date, NASCET, the European Carotid Surgery Trial
(ECST), and the
Veterans Administration (VA) Symptomatic Trial have reported definitive
results. In the NASCET Study, 3 years after entering the first patient
and after 659 patients with stenoses 70% or greater diameter reduction
had been randomly selected, the "stopping rules" were triggered
by the Data and Safety Monitoring Board of the National Institute of
Neurological Disorders and Stroke. This occurred because there was a
clear benefit in favor of carotid endarterectomy. The life table
estimate of cumulative stroke risk in the distribution of the study
artery at 2 years was 26% in 331 medical patients in contrast with 9%
in 328 surgical patients, providing an absolute risk reduction of
17±3.5% (mean±SEM) (P
.001).19 Similar
and
confirmatory findings were noted in the European and VA trials. The
European trial noted significant benefit in favor of surgery for
stenosis >69% but no benefit of surgery in symptomatic patients with
<30% stenosis.51 The VA trial noted the benefit for
prevention of stroke and crescendo TIAs with stenoses as low as
50%.52 NASCET and ECST have not reached definitive
conclusions about symptomatic patients with stenoses between 30% and
69%, and both trials continue to randomize such patients. (Because
ECST calculations use an estimated carotid bulb diameter rather than
the internal carotid artery diameter as the denominator, 70% in ECST
is equivalent to 45% stenosis in NASCET.)
| Carotid Endarterectomy in Special Circumstances |
|---|
|
|
|---|
Evolving Stroke
Reports on natural history and attempts at
surgical management are
now more than 10 years old and predate current imaging technology. This
makes conclusions in this area impossible and provides an important
area for new
investigation.53 54 55 56 57
Combined Carotid/Coronary Surgery
Patients with either
symptomatic or asymptomatic CAD in the
presence of symptomatic coronary artery disease represent a
difficult decision matrix. The options include operating on the carotid
lesion first, with an increased risk of morbidity and mortality from
myocardial infarction; operating on the coronary lesion first, with an
increased risk of perioperative stroke; operating on both lesions
during the same period of anesthesia; or operating on the coronary
arteries alone. Of the 57 English-language papers on this topic, only
19 report on more than 50 patients. A meta-analysis of 56 reports
reviewed three operative strategies: simultaneous carotid and coronary
artery bypass grafting (CABG), carotid surgery followed by CABG,
and CABG followed by carotid surgery. The meta-analysis indicates
that the perioperative stroke rate was similar if carotid and coronary
surgery were combined or if carotid surgery preceded coronary bypass
grafting. The frequency of stroke was significantly greater if CABG
preceded carotid surgery. However, the frequency of myocardial
infarction (P=.01) and death (P=.02)
were greater when carotid surgery preceded coronary bypass grafting
(Table
).58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121
|
The optimal strategy for management of patients with combined coronary and carotid disease will be established only by a well-designed prospective randomized trial.
Acute Carotid Dissection
Acute dissections of the internal
carotid artery can occur either
spontaneously or after blunt trauma. The pathology is an intimal tear
with an intramural hematoma of the internal carotid artery that can
remain stable, extend along the artery, or expand to produce a
dissecting aneurysm. Thrombi from this site can extend or embolize
intracranially.
This condition is treated medically. In those rare instances when focal ischemic symptoms recur despite medical treatment, and there is an appropriate vascular lesion, surgery may represent an alternative approach.122 123 124 125 126
| Asymptomatic Patients |
|---|
|
|
|---|
|
The presence of ulceration, as documented by angiography, usually performed during evaluation of a symptomatic contralateral carotid artery, has also been a marker for subsequent stroke risk. The size and extent of ulceration has been correlated with the neurological event rate. Using conventional cut-film angiography, the ulcer size can be defined by multiplying the length and width of the ulcer in millimeters. Thus, ulcers that measure <10 mm2 are defined as "A" ulcers; ulcers that range from 10 to 40 mm2 are defined as "B" ulcers; and ulcers that exceed 40 mm2, as "C" ulcers.144 The presence of a "C" ulcer, independent of associated carotid stenosis, identified a group of patients who were at risk of stroke at the rate of 7.5% per year.139 140 The presence of the small "A" ulcers was not associated with an increased stroke risk.144 145 Controversy exists concerning the natural history of the "B" ulcer, with some reports suggesting that the stroke risk in patients associated with "B" ulcers was 4.5% per year139 140 and other reports showing no relation between the presence of a "B" ulcer and subsequent stroke risk.146 147
Results of Carotid Endarterectomy for Asymptomatic Patients
The rationale of carotid endarterectomy for asymptomatic carotid
bifurcation lesions is based on the assumption that there will be a
reduction in long-term stroke risk in the distribution of the artery.
To achieve this objective, the following criteria must be
fulfilled: (1) a lesion must be associated with a demonstrable
stroke risk (2) removal of the lesion must eliminate or
reduce long term stroke risk (3) the surgeon who operates
on the asymptomatic carotid lesion must have a low rate of
perioperative neurological morbidity and mortality.
Perioperative and long-term results of surgical management are readily
available from retrospective reviews. Comparison of these reviews with
the natural history reports has resulted in a series of position or
consensus statements. Finally, prospective randomized trials either
completed or in progress will provide the most definitive evidence
either supporting or refuting the efficacy of prophylactic carotid
endarterectomy in asymptomatic patients.
Recent publications have documented the risk of surgery as ranging from 0.0% to 3.8%.148 149 150 151 A survey of surgeons participating in ACAS yielded an experience of 1511 operations for asymptomatic stenosis with a combined operative mortality and neurological morbidity of 1.7%.32 A review of an experience in the community of Rochester, NY, during the sample years 1984 through 1985 identified 226 carotid endarterectomies performed for asymptomatic carotid stenosis with a combined operative morbidity and mortality of 3.9%.152 Finally, the operative risk in the VA prospective randomized trial demonstrated a combined risk of death and stroke of 4.3% in 211 operations.143 The AHA Stroke Council has stated that for carotid endarterectomy to be efficacious in asymptomatic patients, the target for combined perioperative death and stroke rate should be <3%.153
A review of six series in the literature documented the outcome of patients followed for prolonged intervals after surgery for asymptomatic carotid stenosis. The ipsilateral annual stroke rate, including perioperative stroke, ranged from 0.7% to 2.0% per year.153 154 155 156 157
Position statements concerning the use of prophylactic carotid endarterectomy have been published by the Joint Council of the SVS/ISCVS49 and the Rand Corporation.50 An ad hoc committee of the AMA (D.B. Matchar, MD, C.T. Huesgen, MD, W.S. Moore, MD, unpublished data), and an international consensus conference (A. Nicolaides, MD, unpublished data) have also issued statements on prophylactic carotid endarterectomy. The International Consensus Conference on Asymptomatic Patients With Carotid Bifurcation Disease concluded that
In an effort to clarify the role of carotid endarterectomy in reducing stroke alone or stroke and death, this consensus group supports randomization of patients with severe asymptomatic stenosis to ongoing prospective clinical trials. However, for patients unable or unwilling to participate in these trials, some members of this panel believe that carotid endarterectomy may be considered in good risk patients free of life threatening coronary disease by surgeons with low surgical complications. (A. Nicolaides, MD, unpublished data.)
Five prospective randomized trials were designed to study the efficacy of prophylactic carotid endarterectomy for the treatment of patients with asymptomatic carotid stenosis. The first trial to publish its results, the Carotid Artery Surgery Asymptomatic Narrowing Operation Versus Aspirin (CASANOVA) trial, concluded that carotid endarterectomy was not efficacious when compared with their control group. Unfortunately the study was seriously flawed.158
The Mayo Asymptomatic Carotid Endarterectomy (MACE)159 trial included too few observations of cerebral ischemic events to allow the authors to judge between the medical and surgical treatment groups. This trial was stopped early because of the frequency of a secondary end point (myocardial infarction) in the randomized surgical group, an end point that was significantly greater than in the medical part of the trial. Surgical patients in this trial had been discouraged from taking aspirin unless other indications (eg, cardiac) existed for its use.
The VA trial143 was designed to test the hypothesis that carotid endarterectomy plus aspirin antiplatelet therapy would be more effective than antiplatelet therapy alone in reducing the incidence of neurological events, including TIA and stroke. The results of this study proved the hypothesis and demonstrated that the combined incidence of ipsilateral neurological events in the surgical group was 8% in contrast to 20.6% in the medical group (P<.001). Unfortunately, when the study was designed, the proposed sample size was not large enough to provide statistical power to show a difference for stroke alone. Nonetheless, after a 4-year follow-up interval, the ipsilateral stroke rate in the surgical group was 4.7% (including perioperative strokes), in contrast to 9.4% in the medical group (P=.056). However, when perioperative mortality (1.9%) was added to the surgical stroke rate, the difference between the two groups with respect to stroke failed to reach statistical significance. As a consequence, this trial has failed to resolve the controversy.
ACAS, the largest of the five trials, was originally designed to randomly assign 1500 patients to best medical management or surgery plus best medical management. ACAS investigators received permission to expand the sample size to ensure that there are a sufficient number of patients to be able to consider differences in the end point of stroke alone. At this time entry to the trial is complete, with 1662 patients randomized, and the follow-up phase is in progress.160
On September 28, 1994, the NINDS issued a clinical advisory indicating a clear benefit in favor of surgery and that the trial has been halted. There was a relative reduction in risk for stroke of 55% in the surgical group compared with the group of patients who did not undergo surgery. The manuscript documenting the results of the ACAS study is in preparation.
The Asymptomatic Carotid Surgery Trial (ACST) has started randomizing patients from approximately 100 centers around Europe. Details on plaque characterization are included to test the hypothesis that echolucent plaques are more hazardous.
| Analysis of Surgical Risk for All Indications |
|---|
|
|
|---|
Operative risk, as a function of patient selection, is determined not only by a patient's general state of health but also by the indication for surgery. A review of the medical literature clearly shows that the lowest complication rates occur with operations on asymptomatic patients. The risk of operation is slightly higher in patients suffering transient cerebral ischemia and appears to be highest in patients who have had a prior stroke, particularly in those who have a greater residual neurological deficit.32 161
It is not possible to assign a generic risk for the operation since major factors associated with operative risk will include the expertise of the surgeon performing the operation and the quality of care available in the hospital in which the operation is performed. Morbidity and mortality data extracted from retrospective reviews tend to be of limited value, inasmuch as they represent the experience of the surgeon or surgeons preparing the report. Population-based community audits provide better insight into the average risk of perioperative complications. These numbers, however, are influenced by the patient selection process and surgical expertise in the community being audited. Results of five community-based audits have demonstrated that the percentage of patients disabled or dead following carotid endarterectomy ranges from a low of 4.8% to a high of 9.0%.140 162 163 164 165
An ad hoc committee of the AHA Stroke Council reviewed available reports and made recommendations with regard to the upper acceptable level of risk for combined death and/or stroke associated with carotid endarterectomy as a function of indication for surgery. The limits set were 3% for asymptomatic patients, 5% for patients experiencing transient cerebral ischemia, 7% for patients who have suffered a prior stroke, and 10% for patients undergoing surgery for recurrent stenosis.153 More recently, many series have been reported with complications lower than the upper acceptable limits defined.
It is clear that some surgeons perform this operation with low risk while others have an unacceptably high complication rate; thus, it would be desirable to develop methods for auditing the individual surgeon's practice of carotid endarterectomy and to limit surgical privileges to those who can document that their results fall within an acceptable range. The design of an audit should ensure objective, unbiased, factual information regarding surgical morbidity and mortality. Such an audit should include the following safeguards:
(1) An institutionally based, computerized registry of the results of all carotid endarterectomies should be maintained on an ongoing basis.
(2) An external review should be conducted by an independent observer, eg, a PSRO (professional standards review organization) nurse, of selected records of patients undergoing carotid endarterectomy to ensure that all major complications are accurately reported to the registry.
(3) Performance standards should be established to define acceptable surgical volume as well as upper acceptable limits of morbidity/mortality before a chart review is begun. Large, retrospective, multi-institutional data as well as recommendations by the AHA can be used to help define acceptable norms for each indication for carotid endarterectomy.
(4) The registry should be regularly audited, and the results should be made available to each surgeon promptly. Safeguards should be instituted to provide rigorous confidentiality.
(5) When complications significantly exceed the acceptable limits, an institutional peer review committee should investigate. If extenuating circumstances cannot be identified, appropriate corrective action, which can range from careful monitoring of the surgeon's subsequent endarterectomies to actual loss of hospital privileges to perform the procedure, should be implemented.166 167 168 The results of the audit also can be used to identify problems with and improve care within the institution.
| Reporting Standards |
|---|
|
|
|---|
| Cost-Effectiveness of Carotid Endarterectomy in Stroke Prevention |
|---|
|
|
|---|
It has been difficult to determine the exact cost to the healthcare system of treating an individual with stroke due to the paucity of comprehensive surveys of costs for patients. Also, it is difficult to extract the true costs of medical resources used from either charges or actual reimbursement. However, Medicare claims data as well as published non-US reports suggest that the estimated average direct lifetime medical cost attributable to an incident of stroke range from $30 000 to $60 000.172 173 174 For a patient who may require substantial posthospital services, this amount can be significantly higher. Clearly, more data on direct and indirect costs of the care of the patient with stroke related to CAD are needed.
The cost of carotid endarterectomy, including patient evaluation, special consultation, surgeon's and anesthesiologist's fees, and hospitalization, also varies considerably. Based on 1991 Medicare claims data, the average estimated cost for a carotid endarterectomy is approximately $11 000. The cost may be much higher depending on the extent of preoperative evaluation and complications. Counterbalancing this expenditure is the cost savings that result from strokes avoided. The symptomatic trials suggest that operating on 100 patients with high-grade (>70%) carotid stenosis would lead to 17 fewer strokes over 2 years. The savings in direct costs attributable to this reduction in stroke risk can be broadly estimated to range from $5100 to $10 200 per patient undergoing surgery. Improved quality of life for the patient and family and savings in indirect costs by preventing stroke are inestimable but undoubtedly quite large.
Cost-effectiveness analysis provides another useful perspective on carotid endarterectomy. For symptomatic patients, the strategy of performing angiography and operating on individuals with high-grade carotid stenosis is both medically beneficial and cost-effective. The additional cost per healthcare benefit gained (marginal cost-effectiveness ratio) compares favorably with other accepted medical practices. The cost effectiveness of carotid endarterectomy for asymptomatic stenosis will depend on the frequency and severity of neurological deficits in surgically treated versus medically treated patients. Until more data from randomized studies are available, this aspect of cost effectiveness cannot be predicted. However, the lower frequency of stroke in patients with asymptomatic stenosis suggests that the cost effectiveness of endarterectomy for this group will be less than that for patients with symptomatic lesions. For the same reason, it appears that the cost of large-scale screening programs would likely negate any potential cost benefit of surgery for asymptomatic stenosis. Therefore, unless we can further identify subsets of patients who are at particularly high risk for stroke, the benefit of performing carotid endarterectomy indiscriminately on asymptomatic patients with carotid stenosis will likely be largely outweighed by the cost of screening.
| Definition of Terms Used in Indications for Carotid Endarterectomy |
|---|
|
|
|---|
Definitions of Ranks for Surgical Indication for Carotid
Endarterectomy
Four choices were available for each indication as a
function of
surgical risk. For asymptomatic patients, the options for surgical risk
for combined stroke and death as a consequence of operation were <3%,
3% to 5%, and 5% to 10%. For symptomatic patients, the surgical
risk options were <6% and 6% to 10%.
Surgical risk is based on a combined estimate of the patient's general medical fitness to undergo surgery and the individual surgeon's risk of morbidity and mortality for patients with a specific surgical indication.
A surgical indication that carries a high benefit-to-risk ratio would be acceptable in patients who were at higher surgical risk, whereas a surgical indication that had a lower benefit-to-risk ratio might be acceptable in only the best-risk patients.
Proven
(Score=1)
This designation constitutes the strongest indication
for carotid
endarterectomy and strongly implies that to withhold surgery in the
presence of this indication would be inappropriate under normal
circumstances. Indications classified as proven are generally supported
by data from contemporary, prospective, randomized clinical trials.
Acceptable but Not Proven (Score=2)
There is
general agreement that this represents a good
indication for surgery, with the expectation that benefits outweigh the
risks. This rank is supported by promising, but not scientifically
certain, data. Indications in this category may be the subject of
ongoing prospective randomized trials. In that case, it is expected
that patients will be offered the opportunity to participate in the
trial. However, when this is not possible, either by geography or
patient preference, surgery would be an acceptable alternative at the
present level of knowledge.
Uncertain (Score=3)
There are insufficient data to define the risk/benefit ratio.
These potential indications should be evaluated in clinical trials.
Proven Inappropriate (Score=4)
The current
database is adequate to indicate that the stated risks
of carotid endarterectomy outweigh the benefits. In general, the
database includes contemporary, prospective, randomized clinical
trials.
Definitions of Stroke Categories
Mild Stroke
The residual neurological symptoms and signs of a mild stroke
cause no important functional impairment.
Moderate Stroke
The residual neurological symptoms and signs of a moderate stroke
result in a loss of function that may be complete in one domain (eg,
arm or leg function, speech loss) and incomplete in others, but the
total functional loss still allows independent existence.
Severe Stroke
Residual neurological signs of a
severe stroke are directly
responsible for the patient's loss of independence.
| Current Indications for Carotid Endarterectomy |
|---|
|
|
|---|
2.
Acceptable but not proven indications: ipsilateral carotid
endarterectomy for stenosis
75% with or without ulceration,
irrespective of contralateral artery status, ranging from no disease to
total occlusion1
3. Uncertain indications
Stenosis
<50% with a "B" or "C" ulcer irrespective
of contralateral internal carotid artery status
Unilateral
carotid endarterectomy with CABG, coronary bypass
graft required with bilateral asymptomatic stenosis >70%
Unilateral carotid stenosis >70%, CABG required, unilateral
carotid endarterectomy with CABG
4. Proven inappropriate indications: none defined
For Patients With a Surgical Risk of 3% to 5%
1. Proven indications: none
2. Acceptable but not proven
indications: ipsilateral carotid
endarterectomy for stenosis
75% with or without ulceration but in
the presence of contralateral internal carotid artery stenosis ranging
from 75% to total occlusion
3. Uncertain indications
Ipsilateral carotid endarterectomy for stenosis
75% with or
without ulceration irrespective of contralateral artery status, ranging
from no stenosis to occlusion
Coronary bypass graft required,
with bilateral asymptomatic
stenosis >70%, unilateral carotid endarterectomy with CABG
Unilateral carotid stenosis >70%, CABG required, ipsilateral
carotid endarterectomy with CABG
4. Proven inappropriate indications: none defined
For Patients With a Surgical Risk of 5% to 10%
1. Proven indications: none
2. Acceptable but not proven indications: none
3. Uncertain indications
Coronary
bypass graft required with bilateral asymptomatic
stenosis >70%, unilateral carotid endarterectomy with CABG
Unilateral carotid stenosis >70%, CABG required, ipsilateral
carotid endarterectomy with CABG
4. Proven inappropriate indications
Ipsilateral carotid endarterectomy for stenosis
75% with or
without ulceration irrespective of contralateral internal carotid
artery status
Stenosis
50% with or without ulceration
irrespective of
contralateral carotid artery status
Symptomatic Patients With CAD
For Patients With a
Surgical Risk of <6%
1. Proven indications
Single or
multiple TIAs within a 6-month interval or crescendo
TIAs in the presence of a stenosis
70%, with or without ulceration,
with or without antiplatelet therapy
Mild stroke within a
6-month interval, in the presence of a
stenosis
70%, with or without ulceration, with or without
antiplatelet therapy
2. Acceptable but not proven indications
TIA (single, multiple, or recurrent) within a 6- month
interval, in the presence of a stenosis
50%, with or without
ulceration, with or without antiplatelet therapy
Crescendo TIAs
in the presence of a stenosis >50%, with or
without ulceration, with or without antiplatelet therapy
Progressive stroke in the presence of a stenosis
70%, with
or
without ulceration, with or without antiplatelet therapy
Mild
stroke in the presence of a stenosis
50%, with or
without ulceration, with or without antiplatelet therapy
Moderate stroke in the presence of a stenosis
50%, with or
without ulceration, with or without antiplatelet therapy
Ipsilateral carotid endarterectomy combined with CABG in a
patient experiencing TIAs, in the presence of unilateral or bilateral
stenoses
70%, coronary bypass grafting needed
3. Uncertain indications
TIA (single, multiple, or recurrent) with stenosis
<50% with
or without ulceration, with or without antiplatelet therapy
Crescendo TIAs, with or without ulceration, and a stenosis
<50%
TIAs in a patient who requires coronary bypass grafting
and has
a stenosis <70%
Mild stroke with carotid stenosis <50%,
with or without
ulceration, with or without antiplatelet therapy
Moderate
stroke with carotid stenosis <69%, with or without
ulceration, with or without antiplatelet therapy
Evolving
stroke with carotid stenosis <69%, with or
without ulceration, with or without antiplatelet therapy
Global
ischemic symptoms with ipsilateral carotid stenosis
>75% but contralateral stenosis <75%, with or without ulceration,
with or without antiplatelet therapy
Acute dissection of
internal carotid artery with persistent
symptoms while on heparin
Acute carotid occlusion, diagnosed
within 6 hours, producing
transient ischemic events
Acute carotid occlusion, diagnosed
within 6 hours, producing a
mild stroke
4. Proven inappropriate indications
Moderate
stroke with stenosis <50%, not on aspirin
Evolving stroke
with stenosis <50%, not on aspirin
Acute internal carotid
artery dissection, asymptomatic, on
heparin
For Patients With a Surgical Risk of 6% to 10%
1. Proven indications: none
2. Acceptable but not proven indications
Single or multiple TIAs within a 6-month interval,
in the
presence of a carotid stenosis
70%, with or without ulceration, with
or without antiplatelet therapy
Recurrent TIAs, while on
antiplatelet drugs, for a carotid
stenosis
50% in the presence of ulceration, or
70% with or
without ulceration
Crescendo TIAs with a stenosis
50%, with
or without
ulceration, with or without antiplatelet therapy
Mild stroke in
the presence of a stenosis >70%, with or
without ulceration, with or without antiplatelet therapy
Moderate stroke with a stenosis >70%, with or without
ulceration, with or without antiplatelet therapy
Evolving
stroke in the presence of a >70% stenosis with large
ulceration
3. Uncertain indications
Single TIA with
stenosis <70%, with or without ulceration, with
or without antiplatelet therapy
Multiple TIAs within 6 months
with stenosis <70%, not on
antiplatelet drugs, with or without ulceration
Recurrent TIAs
while on antiplatelet drugs with stenosis <70%,
with or without ulceration
Crescendo